Reify Health thinks clinical trials can be representative by 2030 — and it’s secured the capital to help partners put in the work
Drug developers have lacked on the diversity front for years, especially when it comes to testing investigational treatments, vaccines and other tools to fight diseases.
The industry has beefed up resources and initiatives in recent years, but the problem is likely to take years and years of work to ensure clinical trials are representative of the population and the people that are disproportionately affected by certain diseases. And the FDA released new draft guidance last week to tell drugmakers and medical device manufacturers that they should set goals for enrollment and specify their retention strategies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.